Thoracic surgeon and mesothelioma visionary Dr. David Sugarbaker already is thinking two steps ahead, anticipating the optimal utilization of this latest clinical trial drug combination. That’s what leaders do. A phase II, multicenter clinical trial involving the antibody-drug conjugate anetumab ravtansine (BAY 94-9343) for patients with stage IV pleural mesothelioma opened recently with considerable expectations,…
The post Sugarbaker: Mesothelioma Clinical Trial May Be ‘Home Run’ appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.
[…]